CR9097A - Formulaciones inmunoterapeuticas para la induccion de autoanticuerpos bloqueadores de la union de interleucina-2 a su receptor. su uso en tratamiento del cancer - Google Patents

Formulaciones inmunoterapeuticas para la induccion de autoanticuerpos bloqueadores de la union de interleucina-2 a su receptor. su uso en tratamiento del cancer

Info

Publication number
CR9097A
CR9097A CR9097A CR9097A CR9097A CR 9097 A CR9097 A CR 9097A CR 9097 A CR9097 A CR 9097A CR 9097 A CR9097 A CR 9097A CR 9097 A CR9097 A CR 9097A
Authority
CR
Costa Rica
Prior art keywords
blocking
induction
authortic
interleucine
union
Prior art date
Application number
CR9097A
Other languages
English (en)
Inventor
Enrique Montero Casimiro Jose
N Bladimir Alonso Sarduy Liv
Perez Rodriguez Rolando
Bienvenido Lage Davila Agustin
Original Assignee
Ct De Inmunolog A Molecular
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct De Inmunolog A Molecular filed Critical Ct De Inmunolog A Molecular
Publication of CR9097A publication Critical patent/CR9097A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invencion se relaciona con formulaciones farmaceuticas utiles en el cancer mediante el bloqueo de la union de la Interleukin 2 (IL-2) a su receptor. Mas particularmente la presente invencion se relaciona con formulaciones terapeuticas capaces de incrementar la inmunogenicidad de la IL-2 por su acoplamiento a la proteina transportadora P64k de la Neisseria Meningitidis en adyuvante Montanide ISA 51 para la induccion de autoanticuerpos bloqueadores de la IL-2 a su receptor y metodos efectivos para el tratamiento de tumores, incluyendo cancer de mama.
CR9097A 2004-11-16 2007-05-04 Formulaciones inmunoterapeuticas para la induccion de autoanticuerpos bloqueadores de la union de interleucina-2 a su receptor. su uso en tratamiento del cancer CR9097A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU20040261A CU23297A1 (es) 2004-11-16 2004-11-16 Formulaciones inmunoterapã0/00uticas para la inducciã"n de autoanticuerpos bloqueadores de la uniã"n de interleucina-2 a su receptor. su uso en el tratamiento del cã ncer

Publications (1)

Publication Number Publication Date
CR9097A true CR9097A (es) 2007-08-28

Family

ID=40122436

Family Applications (1)

Application Number Title Priority Date Filing Date
CR9097A CR9097A (es) 2004-11-16 2007-05-04 Formulaciones inmunoterapeuticas para la induccion de autoanticuerpos bloqueadores de la union de interleucina-2 a su receptor. su uso en tratamiento del cancer

Country Status (24)

Country Link
US (1) US20090274647A1 (es)
EP (2) EP1829893B1 (es)
JP (1) JP5227028B2 (es)
KR (1) KR101240457B1 (es)
CN (1) CN101061136B (es)
AR (1) AR051494A1 (es)
AT (1) ATE525393T1 (es)
AU (1) AU2005306186B2 (es)
BR (1) BRPI0518007A (es)
CA (1) CA2588573C (es)
CR (1) CR9097A (es)
CU (1) CU23297A1 (es)
EA (1) EA012072B1 (es)
GE (1) GEP20105039B (es)
MA (1) MA29044B1 (es)
MX (1) MX2007005808A (es)
MY (1) MY162106A (es)
PE (1) PE20061172A1 (es)
SG (1) SG122897A1 (es)
TN (1) TNSN07187A1 (es)
TR (1) TR200704213T2 (es)
TW (1) TWI433853B (es)
WO (1) WO2006053508A1 (es)
ZA (1) ZA200703528B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007271398B2 (en) * 2006-07-06 2013-06-20 Merck Patent Gmbh Compositions and methods for enhancing the efficacy of IL-2 mediated immune responses
WO2015162124A1 (en) * 2014-04-22 2015-10-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the diagnostic of an autoimmune disease
CN115636880A (zh) 2015-10-23 2023-01-24 辉瑞有限公司 抗il-2抗体及其组合物和用途
MY206158A (en) 2017-05-24 2024-12-02 Novartis Ag Antibody-cytokine engrafted proteins and methods of use in the treatment of cancer
CU24734B1 (es) * 2021-03-30 2025-02-07 Ct Inmunologia Molecular Composicones vacunales depletantes de factores de crecimiento hematopoyéticos para el tratamiento de enfermedades inflamatorias

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5939832A (ja) * 1982-08-28 1984-03-05 Ajinomoto Co Inc モノクロ−ナル抗体ならびにその製法、使用法
EP0111344A2 (en) * 1982-12-13 1984-06-20 Sloan-Kettering Institute For Cancer Research Anti-interleukin-2 monoclonal antibodies
US4569790A (en) * 1984-03-28 1986-02-11 Cetus Corporation Process for recovering microbially produced interleukin-2 and purified recombinant interleukin-2 compositions
US5643565A (en) * 1985-09-20 1997-07-01 Chiron Corporation Human IL-2 as a vaccine adjuvant
KR920703114A (ko) * 1989-07-14 1992-12-17 원본미기재 접합체 백신을 위한 시토킨 및 호르몬 운반체
HUT60768A (en) * 1990-03-16 1992-10-28 Sandoz Ag Process for producing cd25 fixing molecules
CU22302A1 (es) 1990-09-07 1995-01-31 Cigb Secuencia nucleotidica codificante para una proteina de la membrana externa de neisseria meningitidis y uso de dicha proteina en preparados vacunales
US5830452A (en) * 1990-11-20 1998-11-03 Chiron Corporation Method for enhancing the anti-tumor therapeutic index of interleukin-2
JPH10147952A (ja) 1996-11-18 1998-06-02 Komatsu Ltd ブルドーザのドージング装置
US20040156824A1 (en) * 1996-12-23 2004-08-12 Epstein Alan L. Vasopermeability enhancing peptide of human interleukin-2 and immunoconjugates thereof
CA2219961C (en) * 1998-01-09 2010-06-01 The University Of Southern California Vasopermeability enhancing peptide of human interleukin-2 and immunoconjugates thereof
CU22731A1 (es) * 1998-02-05 2002-02-28 Centro Inmunologia Molecular Anticuerpo monoclonal que reconoce el oligosacárido ácido siálico n´glicolilado-galactosa-glucosa (ngcneu-gal-glu) en tumores malignos y composiciones farmacéuticas que los contienen
US6168785B1 (en) * 1998-07-16 2001-01-02 Institut Pasteur Biological applications of new peptides of IL-2 and derivatives and use as therapeutic agents
EP1156823B1 (en) * 1999-02-12 2008-10-29 The Scripps Research Institute Methods for treatment of tumors and metastases using a combination of anti-angiogenic and immuno therapies
WO2001080889A1 (en) * 2000-04-26 2001-11-01 National Jewish Medical And Research Center Product and process for regulation of t cell responses
CU23011A1 (es) * 2000-11-03 2004-12-17 Ct Ingenieria Genetica Biotech Método de obtención de estructuras antigénicas quemétodo de obtención de estructuras antigénicas que potencian la reactividad cruzada específica y su potencian la reactividad cruzada específica y su uso en formulaciones uso en formulaciones
CU23077A1 (es) * 2000-12-06 2005-08-17 Centro Inmunologia Molecular Composicion vacunal que contiene factor de crecimiento transformante (tgf-alfa). su uso en la terapia de enfermedades malignas
CU22979A1 (es) * 2000-12-08 2004-09-09 Centro Inmunologia Molecular Combinación inmunoterapéutica para el tratamiento de tumores que sobre-expresan receptores con actividad quinasa en residuos de tirosina
CU22999A1 (es) * 2001-12-04 2004-10-12 Centro Inmunologia Molecular Método de tratamiento de enfermedades malignas e infecciosas crónicas
WO2002087304A2 (de) * 2001-04-30 2002-11-07 Frohnhofen, Wilfried Il2-peptide; von interleukin 2 abgeleitete peptide und peptid-dimere
US6906169B2 (en) * 2001-05-25 2005-06-14 United Biomedical, Inc. Immunogenic peptide composition comprising measles virus Fprotein Thelper cell epitope (MUFThl-16) and N-terminus of β-amyloid peptide
DE60235041D1 (de) * 2001-11-30 2010-02-25 Us Gov Health & Human Serv Und ihre verwendung
ITMI20012527A1 (it) 2001-11-30 2003-05-30 Unihart Corp Proteine di fusione contenenti peptidi tlp
US20040208869A1 (en) * 2003-01-30 2004-10-21 Medimmune, Inc. Uses of anti-integrin alphanubeta3 antibody formulations
US7569215B2 (en) * 2003-07-18 2009-08-04 Massachusetts Institute Of Technology Mutant interleukin-2 (IL-2) polypeptides

Also Published As

Publication number Publication date
KR20070084025A (ko) 2007-08-24
KR101240457B1 (ko) 2013-03-08
JP2008526686A (ja) 2008-07-24
AR051494A1 (es) 2007-01-17
SG122897A1 (en) 2006-06-29
EP2112160A2 (en) 2009-10-28
HK1113374A1 (en) 2008-10-03
CU23297A1 (es) 2008-07-24
EP1829893B1 (en) 2011-09-21
CA2588573C (en) 2013-12-31
TWI433853B (zh) 2014-04-11
EA200701071A1 (ru) 2007-12-28
CN101061136B (zh) 2012-12-05
TNSN07187A1 (en) 2008-11-21
AU2005306186A1 (en) 2006-05-26
AU2005306186B2 (en) 2012-05-31
TR200704213T2 (tr) 2007-08-21
BRPI0518007A (pt) 2008-10-21
EP1829893A1 (en) 2007-09-05
EA012072B1 (ru) 2009-08-28
MX2007005808A (es) 2007-07-20
EP2112160A3 (en) 2010-01-13
GEP20105039B (en) 2010-07-12
WO2006053508A1 (es) 2006-05-26
TW200631591A (en) 2006-09-16
CA2588573A1 (en) 2006-05-26
EP2112160B1 (en) 2015-07-08
MY162106A (en) 2017-05-31
CN101061136A (zh) 2007-10-24
MA29044B1 (fr) 2007-11-01
ATE525393T1 (de) 2011-10-15
PE20061172A1 (es) 2006-12-16
JP5227028B2 (ja) 2013-07-03
US20090274647A1 (en) 2009-11-05
ZA200703528B (en) 2008-06-25

Similar Documents

Publication Publication Date Title
ES2337399T3 (es) Peptidos asociados a tumores unidos promiscuamente a moleculas del antigeno de leucocito humano (hla) de clase ii.
UA103202C2 (ru) Фармацевтическая композиция опухолеассоциированных пептидов и ее применение для лечения раковых заболеваний
PL1922334T3 (pl) Peptydy towarzyszące nowotworom, wiążące się z cząsteczkami klasy I i II antygenów HLA i związana z nimi szczepionka przeciwnowotworowa
MX2009004468A (es) Novedosas formulaciones para vacunas de peptidos asociados a tumores, unidos a moleculas del antigeno de leucocito humano (hla) de clase i o ii.
WO2006081007A3 (en) Use of flagellin in tumor immunotherapy
MX2009009926A (es) Anticuerpo tumor-especifico humano monoclonal.
SI1794190T1 (sl) Imunogeni T-pomagalni epitopi iz humanih tumornih antigenov in imunoterapevtski postopki, ki uporabljajo navedene epitope
CR9097A (es) Formulaciones inmunoterapeuticas para la induccion de autoanticuerpos bloqueadores de la union de interleucina-2 a su receptor. su uso en tratamiento del cancer
BRPI0510570A (pt) composição de vacina
EP4438053A3 (en) An anaplastic lymphoma kinase (alk) cancer vaccine and methods of use
UY29216A1 (es) Formulaciones inmunoterapeúticas para la inducción de autoanticuerpos bloqueadores de la unión de interleucina-2 a su receptor. su uso en el tratamiento del cáncer
DE60325586D1 (de) Mycobakterielle Proteinantigene für Krebstherapie und Impfung
ATE525401T1 (de) Vom tumorantigen 5t4 abgeleitete mhc-klasse-i- und ii-peptidantigene
TH83896A (th) สูตรในการสร้างภูมิคุ้มกันเพื่อก่อให้เกิดออโตแอนติบอดีที่สามารถหลีกเลี่ยงการเชื่อมต่อของอินเตอร์ลิวคิน-2 เข้ากับตัวรับของตัวเอง การใช้สูตรในการบำบัดรักษาโรคมะเร็ง
TH83896B (th) สูตรในการสร้างภูมิคุ้มกันเพื่อก่อให้เกิดออโตแอนติบอดีที่สามารถหลีกเลี่ยงการเชื่อมต่อของอินเตอร์ลิวคิน-2เข้ากับตัวรับของตัวเอง การใช้สูตรในการบำบัดรักษาโรคมะเร็ง
Llopiz-Khatchikian et al. Combined immunization with adjuvant molecules poly (I: C) and anti-CD40 plus a tumor antigen has potent prophylactic and therapeutic antitumor effects

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)